The European Commission's marketing authorization for Pedmarqsi allows Fennec Pharmaceuticals to market and sell the product in the EU. This is the first and only approved therapy for preventing hearing loss in pediatric oncology patients in the region, which could lead to increased demand and revenue for the company. The authorization also comes with 8 years plus 2 years of data and market protection, providing Fennec with a competitive advantage in the market.